More About Daisy
Daisy Wolf is an investing partner at Andreessen Horowitz, where she specializes in healthcare technology. In particular, she focuses on healthcare AI and software, consumer health, and the intersection of healthcare and fintech.
Prior to joining Andreessen Horowitz, Daisy worked at Meta in the Global Business Group, where she led company growth efforts within government and politics. In addition, Daisy has held various roles at multiple startups and covered technology at a hedge fund.
Daisy holds a JD from Yale Law School, an MBA from the Stanford Graduate School of Business, and a BA, Phi Beta Kappa from Yale College.
Latest Content
-
Vijay Pande, general partner, and Daisy Wolf, investing partner, join host Steph Smith on this crossover episode of the a16z podcast.
-
Half of prescribed medications are never taken, and 88% of Americans are metabolically unhealthy. Despite spending 20% of our GDP on healthcare—twice that of any other developed nation—our outcomes still lag behind. In t...
-
Jonathan Swerdlin, cofounder and CEO, and Mark Hyman, MD, cofounder and Chief Medical Officer of Function Health join Vijay Pande, general partner, and Daisy Wolf, investment partner of a16z Bio + Health.
-
Recently, we invested in Function Health, a company that embodies the vision and excitement we had when writing those theses. The one piece we underestimated is the current state of latent demand among consumers for a new approach to healthcare and longevity.
-
The most impactful way to fix healthcare is through improving the consumer experience, which has been largely ignored to date. In today’s modern world where you can order groceries, buy flight tickets, and wire money from your phone, taking care of yourself and navigating the healthcare system remains impossibly hard.
-
Chronis Manolis, SVP and Chief Pharmacy Officer of UPMC Health Plan, joins Julie Yoo, general partner, Daisy Wolf, investment partner, and Will Shrank, venture partner, of a16z Bio + Health.
-
Tom Hale, CEO of ŌURA, joins Vijay Pande, founding partner, and Daisy Wolf, investment partner at a16z Bio + Health.
-
Josh Clemente, cofounder and president of Levels, joins Vijay Pande, founding general partner, and Daisy Wolf, investment partner at a16z Bio + Health.
-
Former gymnast and current investor Aly Raisman joins general partner Julie Yoo and investment partner Daisy Wolf of a16z Bio + Health.
-
100% of stock trades used to be made by humans. Today, 80% are made by computer algorithms. AI is about to bring a similar revolution to healthcare. Over the next few decades, at least half of the $4.3 trillion dollar American healthcare industry will be AI-driven.
-
While the Google --> WebMD --> Friend protocol may be a common way to enter into the healthcare system, it is certainly not an optimal one. Most of us are not well-equipped to self-diagnose from a list of possible conditions, and our friends who work in healthcare often don’t have the exact expertise we need.
-
Building specialist AIs to perform healthcare tasks offers the most challenging technical problems in the field today, as well as the greatest opportunity for impact.
-
We believe that any new technology has to be 10 times better to successfully displace the last one – marginal improvements aren’t worth the effort. Enterprise software struggled to clear that 10x bar in healthcare; AI clears it easily.
-
The most impactful companies are built at the frontier, and healthcare is the next frontier. It’s time to put our tech skills to work. The mother of all markets is ripe for disruption.
-
At a16z, marketplaces represent one of our favorite business models. Our annual Marketplace 100 provides insight into the latest consumer marketplace trends across industries.
-
In this episode, Kurt Adams, CEO of Optum Financial, chats with Daisy Wolf, investment partner for a16z Bio + Health, and Marc Andrusko, investment partner for a16z focused on fintech.
-
Every student can learn, just not on the same day, or the same way. – George Evans
-
Consider this: most healthcare providers are flying blind when it comes to their finances.
-
How are healthtech companies creating sustainable growth paths by selling to SMBs? Can companies solely rely on SMB sales to get to scale, or do they inevitably need to go upmarket (especially during challenging economic times)? We talked to Nancy Ham, the previous CEO of WebPT, Nate Maslak, CEO and cofounder of Ribbon Health, and Oliver Kharraz, CEO and cofounder of ZocDoc, to unpack their SMB-go-to-market strategies. We also surveyed 33 digital health companies that sell to SMBs to gain insight into a broader swath of approaches that upstarts are taking.
-
Bio + Health deal partner Daisy Wolf joins Sarah Thomas, general counsel at Sameday Health, for a fireside chat on the topic of regulation in telehealth—during Covid and on.
-
We think the biggest company in the world will be a consumer health tech company.
-
Most of the wildly successful fintech companies haven’t done much in the healthcare sector. Why?
-
Do SaaS para sistemas operacionais freemium: um novo diferencial para serviços financeiros.
-
Plus, envisioning a new consumer banking stack, Apple & contactless payments, and building to reduce medical debt.
-
2021 saw higher than ever funding of startups, continued maturation of the tech-enabled bio and healthcare landscape, and new platforms and business models that propelled growing levels of adoption and scale amongst both...
